Sort   by:  
 Page size 
UnknownIdentification of Complement-Related Missense Variants in Pediatric Patients with Acute and Post COVID-19 Syndromes
Not available
S-EPMC8701696 | biostudies-literature
TranscriptomicsCCRF-CEM Prednisolone and MG132 treatments at 4h
Background: The combination of Proteasome inhibitor with Glucocorticoid is one of the most promising antileukemic treatments. Both agents act through pluripotent signal mediators. The two types of agents inhibit key signals that are considered crucial to their effects on malignant cells. Methodology...
ORGANISM(S): Homo sapiens 
2011-05-11 | E-GEOD-29136 | biostudies-arrayexpress
UnknownEvaluation and refinement of the PRESTARt tool for identifying 12-14 year olds at high lifetime risk of developing type 2 diabetes compared to a clinicians assessment of risk: a cross-sectional study.
Not available
S-EPMC6659313 | biostudies-literature
UnknownHepatitis B Virus (HBV) Treatment Eligibility in the UK: Retrospective Longitudinal Cohort Data to Explore the Impact of Changes in Clinical Guidelines.
Not available
S-EPMC12548009 | biostudies-literature
UnknownDistinct virologic trajectories in chronic hepatitis B identify heterogeneity in response to nucleos(t)ide analogue therapy.
Not available
S-EPMC11664071 | biostudies-literature
UnknownAdjuvant Olaparib for Patients with <i>BRCA1</i>- or <i>BRCA2</i>-Mutated Breast Cancer.
Not available
S-EPMC9126186 | biostudies-literature
UnknownOverall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer.
Not available
S-EPMC10207856 | biostudies-literature
UnknownMapping the human genetic architecture of COVID-19.
Not available
S-EPMC8674144 | biostudies-literature
Sort   by:  
 Page size